Targeting DNA topoisomerase I with non-camptothecin poisons

Current Medicinal Chemistry

Volumn 19, Issue 8, 2012, Pages 1238-1257

  Beretta, G L ^a   Zuco, V ^a   Perego, P ^a   Zaffaroni, N ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cellular pharmacology; Clinical studies; Dibenzonaphthyridines; DNA topoisomerase I; Drug resistance; Indenoisoquinolines; Indolocarbazoles; Lamellarins; Topopyrones; Tumor cells

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; BERBERINE DERIVATIVE; BMS 250749; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; CORALYNE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ED 110; EDOTECARIN; FAGARONINE; GENZ 644282; INDIMITECAN; INDOTECAN; IRINOTECAN; ISOQUINOLINE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; NITIDINE; PROTOBERBERINE; REBECCAMYCIN; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG;

BREAST CANCER; CELL CYCLE ARREST; CELL DEATH; CLINICAL TRIAL (TOPIC); DRUG STRUCTURE; ENZYME INHIBITION; GENE TARGETING; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SOLID TUMOR; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; DNA TOPOISOMERASES, TYPE I; HUMANS; MOLECULAR STRUCTURE; TOPOISOMERASE INHIBITORS;

EID: 84858208700     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799320529     Document Type: Review

References (180)

1. Bjornsti, M.A.; Benedetti, P.; Viglianti, G.A.; Wang, J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cell to the antitumor drug camptothecin. Cancer Res., 1989, 49(22), 6318-6323. (Pubitemid 20000930)
2. Hsiang, Y.H.; Liu, L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 1988, 48(7), 1722-1726.
3. Pommier, Y.; Cherfils, J. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol. Sci., 2005, 6(3), 138-145. (Pubitemid 40313593)
4. Pommier, Y.; Pourquier, P.; Fan, Y.; Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1998, 1400(1-3), 83-105.
5. Staker, B.L.; Hjerrild, K.; Feese, M.D.; Behnke, C.A.; Burgin, A.B. Jr.; Stewart, L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(24), 15387-15392. (Pubitemid 35403944)
6. Champoux, J.J. DNA Topoisomerases: Structure, Function, and Mechanism. Annu. Rev. Biochem., 2001, 70, 369-413. (Pubitemid 32662215)
7. Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol., 2010; 17(5), 421-433.
8. Pfister, T.D.; Reinhold, W.C.; Agama, K.; Gupta, S.; Khin, S.A.; Kinders, R.J.; Parchment, R.E.; Tomaszewski, J.E.; Doroshow, J.H.; Pommier, Y. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol. Cancer Ther., 2009, 8(7), 1878-1884.
9. Pommier, Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev., 2009, 109(7), 2894-2902.
10. Pratesi, G.; Beretta, G.L.; Zunino, F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs, 2004, 15(6), 545-552. (Pubitemid 38932320)
11. Pisano, C.; De Cesare, M.; Beretta, G.L.; Zuco, V.; Pratesi, G.; Penco, S.; Vesci, L.; Foderà, R.; Ferrara, F.F.; Guglielmi, M.B.; Carminati, P.; Dallavalle, S.; Morini, G.; Merlini, L.; Orlandi, A.; Zunino, F. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol. Cancer Ther., 2008, 7(7), 2051-2059.
12. Beretta, G.L.; Zunino, F. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem. Pharmacol., 2007, 74(10), 1437-1444. (Pubitemid 47575490)
13. Takagi, K.; Dexheimer, T.S.; Redon, C.; Sordet, O.; Agama, K.; Lavielle, G.; Pierré, A.; Bates, S.E.; Pommier, Y. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol. Cancer Ther., 2007, 6(12), 3229-3238.
14. Xiao, X.; Antony, S.; Pommier, Y.; Cushman, M. Total synthesis and biological evaluation of 22-hydroxyacuminatine. J. Med. Chem., 2006, 49(4), 1408-1412. (Pubitemid 43271893)
15. Fox, B.M.; Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Staker, B.L.; Stewart, L.; Cushman, M. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J. Med. Chem., 2003, 46(15), 3275-3282. (Pubitemid 36842411)
16. Cinelli, M.A.; Morrell, A.; Dexheimer, T.S.; Scher, E.S.; Pommier, Y.; Cushman, M. Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J. Med, Chem., 2008, 51(15), 4609-4619.
17. Cinelli, M.A.; Cordero, B.; Dexheimer, T.S.; Pommier, Y.; Cushman, M. Synthesis and biological evaluation of 14-(aminoalkylaminomethyl) aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg. Med. Chem., 2009, 17(20), 7145-7155.
18. Grillet, F.; Baumlová, B.; Prévost, G.; Constant, J.F.; Chaumeron, S.; Bigg, D.C.; Greene, A.E.; Kanazawa, A. Synthesis and bioevaluation of 22- hydroxyacuminatine analogs. Bioorg. Med. Chem Lett., 2008, 18(6), 2143-2146.
19. Cinelli, M.A.; Morrell, A.E.; Dexheimer, T.S.; Agama, K.; Agrawal, S.; Pommier, Y.; Cushman, M. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg. Med. Chem., 2010, 18(15), 5535-5552.
20. De Cesare, M.; Beretta, G.L.; Tinelli, S.; Benedetti, V.; Pratesi, G.; Penco, S.; Dallavalle, S.; Merlini, L.; Pisano, C.; Carminati, P.; Zunino, F. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem. Pharmacol., 2007, 73(5), 656-664. (Pubitemid 46161375)
21. Brangi, M.; Litman, T.; Ciotti, M.; Nishiyama, K.; Kohlhagen, G.; Takimoto, C.; Robey, R.; Pommier, Y.; Fojo, T.; Bates, S.E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 1999, 59(23), 5938-5946. (Pubitemid 30004955)
22. Bates, S.E.; Medina-Pérez, W.Y.; Kohlhagen, G.; Antony, S.; Nadjem, T.; Robey, R.W.; Pommier, Y. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J. Pharmacol. Exp. Ther., 2004, 310(2), 836-842. (Pubitemid 38988932)
23. Liao, Z.; Robey, R.W.; Guirouilh-Barbat, J.; To, K.K.; Polgar, O.; Bates, S.E.; Pommier, Y. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol. Pharmacol., 2008, 73(2), 490-497. (Pubitemid 351159219)
24. Gatti, L.; Beretta, G.L.; Cossa, G.; Zunino, F.; Perego, P. ABC transporters as potential targets for modulation of drug resistance. Mini Rev. Med. Chem., 2009, 9(9), 1102-1112.
25. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6(10), 789-802. (Pubitemid 44450467)
26. Sheng, C.; Miao, Z.; Zhang, W. New Strategies in the Discovery of novel non-camptothecin topoisomerase i inhibitors. Curr. Med. Chem., 2011, 18(28), 4389-409.
27. Staker, B.L.; Feese, M.D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A.B. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem., 2005, 48(7), 2336-2345. (Pubitemid 40516428)
28. Khan, Q.A.; Pilch, D.S. Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J. Mol. Biol., 2007, 365(3), 561-569. (Pubitemid 44960360)
29. Takebayashi, Y.; Pourquier, P.; Yoshida, A.; Kohlhagen, G.; Pommier, Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(13), 7196-7201. (Pubitemid 29299638)
30. Meng, L.H.; Liao, Z.Y.; Pommier, Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem., 2003, 3(3), 305-320.
31. Long, B.H.; Rose, W.C.; Vyas, D.M.; Matson, J.A.; Forenza, S. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Chem Anticancer Agents, 2002, 2(2), 255-266. (Pubitemid 34649875)
32. Pommier, Y.; Cushman, M. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol. Cancer Ther., 2009, 8(5), 1008-1014.
33. Khadka, D.B.; Cho, W.J. 3-Arylisoquinolines as novel topoisomerase I inhibitors. Bioorg Med Chem., 2011, 19(2), 724-734.
34. Lee, S.H.; Van, H.T.; Yang, S.H.; Lee, K.T.; Kwon, Y.; Cho, W.J. Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(9), 2444-1447.
35. Makhey, D.; Li, D.; Zhao, B.; Sim, S.P.; Li, T.K.; Liu,A.; Liu, L.F.; LaVoie, E.J. Substituted benzo[i]phenanthridines as mammalian topoisomerasetargeting agents Bioorg. Med. Chem. 2003, 11(8), 1809-1820. (Pubitemid 36349162)
36. Li, D.; Zhao, B.; Sim, S.P.; Li, T.K.; Liu, A.; Liu, L.F.; LaVoie, E.J. 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg. Med. Chem., 2003, 11(4), 521-528. (Pubitemid 36132229)
37. Ruchelman, A.L.; Singh, S.K.; Wu, X.; Ray, A.; Yang, J.M.; Li, T.K.; Liu, A.; Liu, L.F.; LaVoie, E.J. Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435. Bioorg. Med. Chem. Lett., 2002, 12(22), 3333-3336. (Pubitemid 35248243)
38. Kubová, N.; Smékal, E.; Kleinwächter, V.; Cushman, M. Binding Properties of Nitidine and Its Indenoisoquinoline Analogue with DNA. Studia Biophys., 1986, 114(1-3), 25l-256.
39. Smëkal, E.; Kubová, N.; Kleinwächter, V.; Cushman, M. DNA-Binding Studies-Selected Benzophenanthridine Alkaloids as Binding Probes. Studia Biophys., 1986, 114(1-3), 257-262.
40. Pindur, U.; Kim, Y.S.; Mehrabani, F. Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Curr. Med. Chem., 1999, 6(1), 29-69. (Pubitemid 29068269)
41. Prudhomme, M. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents. Curr. Med. Chem., 2000, 7(12), 1189-1212.
42. Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Carrasco, C.; Ollier, M.; Sevère, D.; Riou, J.F.; Fabbro, D.; Meyer, T.; Aubertin, A.M. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J. Med. Chem., 1998, 41(10), 1631-1640. (Pubitemid 28221956)
43. Bailly, C.; Riou, J.F.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; Prudhomme, M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry, 1997, 36(13), 3917-3929. (Pubitemid 27154713)
44. Denny, W.A. Edotecarin. Drugs, 2004, 7(2), 173-177.
45. Molina-Ruiz, R.; Saíz-Urra, L.; Rodríguez-Borges, J.E.; Pérez-Castillo, Y.; González, M.P.; García-Mera, X.; Cordeiro, M.N. A TOPological Sub-structural Molecular Design (TOPS-MODE)-QSAR approach for modeling the antiproliferative activity against murine leukemia tumor cell line (L1210). Bioorg. Med. Chem., 2009, 17(2), 537-547.
46. Pereira, E.R.; Belin, L.; Sancelme, M.; Prudhomme, M.; Ollier, M.; Rapp, M.; Sevère, D.; Riou, J.F.; Fabbro, D.; Meyer, T. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem., 1996, 39(22), 4471-4477. (Pubitemid 26359403)
47. Voldoire, A.; Sancelme, M.; Prudhomme, M.; Colson, P.; Houssier, C.; Bailly, C.; Léonce, S.; Lambel, S. Rebeccamycin analogues from indolo[2,3-c]carbazole. Bioorg. Med. Chem., 2001, 9(2), 357-365. (Pubitemid 32244034)
48. Prudhomme, M. Rebeccamycin analogues as anti-cancer agents. Eur. J. Med. Chem., 2003, 38(2), 123-140. (Pubitemid 36288468)
49. Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Renard, P.; Prudhomme, M. Syntheses and antiproliferative activities of rebeccamycin analogues bearing two 7-azaindole moieties. Bioorg. Med. Chem., 2003, 11(5), 679-687. (Pubitemid 36132210)
50. Marminon, C.; Pierré, A.; Pfeiffer, B.; Pérez, V.; Léonce, S.; Joubert, A.; Bailly, C.; Renard, P.; Hickman, J.; Prudhomme, M. Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety. J. Med. Chem., 2003, 46(4), 609-622. (Pubitemid 36182762)
51. Moreau, P.; Gaillard, N.; Marminon, C.; Anizon, F.; Dias, N.; Baldeyrou, B.; Bailly, C.; Pierré, A.; Hickman, J.; Pfeiffer, B.; Renard, P.; Prudhomme, M. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives. Bioorg. Med. Chem., 2003, 11(23), 4871-4879. (Pubitemid 37352973)
52. Prudhomme, M. Biological targets of antitumor indolocarbazoles bearing a sugar moiety. Curr. Med. Chem. Anticancer Agents., 2004, 4(6), 509-521. (Pubitemid 39406263)
53. Ohkubo, M.; Nishimura, T.; Kawamoto, H.; Nakano, M.; Honma, T.; Yoshinari, T.; Arakawa, H.; Suda, H.; Morishima, H.; Nishimura, S. Synthesis and biological activities of NB-506 analogues modified at the glucose group. Bioorg. Med. Chem. Lett., 2000, 10(5), 419-422. (Pubitemid 30153604)
54. Bailly, C.; Qu, X.; Anizon, F.; Prudhomme, M.; Riou, J.F.; Chaires, J.B. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol. Pharmacol., 1999, 55(2), 377-385. (Pubitemid 29076036)
55. Cipollone, A.; Berettoni, M.; Bigioni, M.; Binaschi, M.; Cermele, C.; Monteagudo, E.; Olivieri, L.; Palomba, D.; Animati, F.; Goso, C.; Maggi, C.A. Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activity. Bioorg. Med. Chem., 2002, 10(5), 1459-1470. (Pubitemid 34214709)
56. Facompre, M.; Carrasco, C.; Colson, P.; Houssier, C.; Chisholm, J.D., Van Vranken, D.L.; Bailly, C. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles. Mol. Pharmacol., 2002, 62(5), 1215-1227. (Pubitemid 35222514)
57. Animati, F.; Berettoni, M.; Bigioni, M.; Binaschi, M.; Felicetti, P.; Gontrani, L.; Incani, O.; Madami, A.; Monteagudo, E.; Olivieri, L.; Resta, S.; Rossi, C.; Cipollone, A. Synthesis, biological evaluation, and molecular modelling studies of rebeccamycin analogues modified in the carbohydrate moiety. Chem. Med. Chem., 2008, 3(2), 266-279.
58. Cushman, M.; Cheng, L. Stereoselective oxidation by thionyl chloride leadingto the indeno[1,2-c]isoquinoline system. J. Org. Chem., 1978, 43, 3781-3783.
59. Kohlhagen, G.; Paull, K.D.; Cushman, M.; Nagafuji, P.; Pommier, Y. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol., 1998, 54(1), 50-58. (Pubitemid 28337586)
60. Jayaraman, M.; Fox, B.M.; Hollingshead, M.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of New Dihydroindeno[1,2-c]isoquinoline and Indenoisoquinolinium Chloride Topoisomerase I Inhibitors Having High in vivo Anticancer Activity in the Hollow Fiber Animal Model. J Med Chem., 2002, 45(1), 242-249. (Pubitemid 34038558)
61. Morrell, A.; Jayaraman, M.; Nagarajan, M.; Fox, B.M.; Meckley, M.R.; Ioanoviciu, A.; Pommier, Y.; Antony, S.; Hollingshead, M.; Cushman, M. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay. Bioorg Med Chem Lett., 2006, 16(16), 4395-4399. (Pubitemid 44026675)
62. Strumberg, D.; Pommier, Y.; Paull, K.; Jayaraman, M.; Nagafuji, P.; Cushman, M. Synthesis of Cytotoxic Indenoisoquinoline Topoisomerase I Poisons. J. Med. Chem., 1999, 42(3), 446-457. (Pubitemid 29085106)
63. Nagarajan, M.; Morrell, A.; Fort, B.C.; Meckley, M.R.; Antony, S.; Kohlhagen, G.; Pommier, Y. Cushman M. Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings. J. Med. Chem., 2004, 47(23), 5651-5661. (Pubitemid 39447262)
64. Khadka, D.B.; Le, Q.M.; Yang, S.H.; Van, H.T.; Le, T.N.; Cho, S.H.; Kwon, Y.; Lee, K.T.; Lee, E.S.; Cho, W.J. Design, synthesis and docking study of 5-amino substituted indeno[1,2-c]isoquinolines as novel topoisomerase I inhibitors. Bioorg. Med. Chem., 2011, 19(6), 1924-1929.
65. Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Design, synthesis, and biological evaluation of cytotoxic 11- aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors. Bioorg. Med. Chem., 2004, 12(19), 5147-5160. (Pubitemid 39200616)
66. Xiao, X.; Miao, Z.H.; Antony, S.; Pommier, Y.; Cushman, M. Dihydroindenoisoquinolines function as prodrugs of indenoisoquinolines. Bioorg. Med. Chem. Lett., 2005, 15(11), 2795-2798. (Pubitemid 40732222)
67. Morrell, A.; Placzek, M.S.; Steffen, J.D.; Antony, S.; Agama, K.; Pommier, Y.; Cushman, M. Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J. Med. Chem., 2007, 50(9), 2040-2048. (Pubitemid 46683057)
68. Cushman, M.; Jayaraman, M.; Vroman, J.A.; Fukunaga, A.K.; Fox, B.M.; Kohlhagen, G.; Strumberg, D.; Pommier, Y. Synthesis of new indeno[1,2-c] isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J. Med. Chem., 2000, 43(20), 3688-3698.
69. Morrell, A.; Placzek, M.; Parmley, S.; Grella, B.; Antony, S.; Pommier, Y.; Cushman, M. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J. Med. Chem., 2007, 50(18), 4388-4404. (Pubitemid 47378837)
70. Nagarajan, M.; Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen. J. Med. Chem., 2003, 46(26), 5712-5724. (Pubitemid 37543321)
71. Morrell, A.; Placzek, M.; Parmley, S.; Antony, S.; Dexheimer, T.S.; Pommier, Y.; Cushman, M. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J. Med. Chem., 2007, 50(18), 4419-4430. (Pubitemid 47378839)
72. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J. Med. Chem., 2006, 49(26), 7740-7753. (Pubitemid 46033665)
73. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors. Bioorg Med Chem Lett. 2004, 14(14),3659-3663. (Pubitemid 38760058)
74. Nagarajan, M.; Morrell, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Pommier, Y.; Ragazzon, P.A.; Garbett, N.C.; Chaires, J.B.; Hollingshead, M.; Cushman, M. Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors. J. Med. Chem., 2006, 49(17), 5129-5140. (Pubitemid 44260209)
75. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(7), 1846-1849. (Pubitemid 43267363)
76. Nagarajan, M.; Morrell, A.; Ioanoviciu, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Hollingshead, M.; Pommier, Y.; Cushman, M. Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J. Med. Chem., 2006, 49(21), 6283-6289. (Pubitemid 44595205)
77. Peterson, K.E.; Cinelli, M.A.; Morrell, A.E.; Mehta, A.; Dexheimer, T.S.; Agama, K.; Antony, S.; Pommier, Y.; Cushman, M. Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. J. Med. Chem., 2011, 54(14), 4937-4953.
78. Bakshi, R.P.; Sang, D.; Morrell, A.; Cushman, M.; Shapiro, T.A. Activity of indenoisoquinolines against African trypanosomes. Antimicrob Agents Chemother., 2009, 53(1), 123-128.
79. Kiselev, E.; Deguire, S.; Morrell, A.; Agama, K.; Dexheimer, T.S.; Pommier, Y.; Cushman, M. 7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents. J. Med. Chem., 2011, 54(17), 6106-6116.
80. Antony, S.; Agama, K.K.; Miao, Z.H.; Hollingshead, M.; Holbeck, S.L.; Wright, M.H.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier Y. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c] isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol. Pharmacol., 2006, 70(3), 1109-1120. (Pubitemid 44268468)
81. Van, H.T.; Cho, W.J. Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study. Bioorg. Med. Chem. Lett., 2009, 19(9), 2551-2554.
82. Ioanoviciu, A.; Antony, S.; Pommier, Y.; Staker, B.L.; Stewart, L.; Cushman, M. Synthesis and Mechanism of Action Studies of a Series of Norindenoisoquinoline Topoisomerase I Poisons Reveal an Inhibitor with a Flipped Orientation in the Ternary DNA-Enzyme-Inhibitor Complex as Determined by X-ray Crystallographic Analysis. J. Med. Chem., 2005, 48(15), 4803-4814. (Pubitemid 41033123)
83. Song, Y.; Shao, Z.; Dexheimer, T.S.; Scher, E.S.; Pommier, Y.; Cushman, M. Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J. Med. Chem., 2010, 53(5), 1979-1989.
84. Kettmann, V.; Kost'álová, D.; Höltje, H.D. Human topoisomerase I poisoning: docking protoberberines into a structure-based binding site model. J. Comput. Aided Mol. Dis., 2004, 18(12), 785-796.
85. Kuo, C.L.; Chou, C.C.; Yung, B.Y. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett., 1995, 93(2), 193-200.
86. Li, T.K.; Bathory, E.; LaVoie, E.J.; Srinivasan, A.R.; Olson, W.K.; Sauers, R.R.; Liu, L.F., Pilch, D.S. Human topoisomerase I poisoning by protoberberines: potential roles for both drug-DNA and drug-enzyme interactions. Biochemistry, 2000, 39(24), 7107-7116. (Pubitemid 30413099)
87. Pilch, D.S.; Yu, C.; Makhey, D.; LaVoie, E.J.; Srinivasan, A.R.; Olson, W.K.; Sauers, R.R.; Breslauer, K.J.; Geacintov, N.E.; Liu, L.F. Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs. Biochemistry, 1997, 36(41), 12542-12553. (Pubitemid 27446678)
88. Laco, G.S.; Collins, J.R.; Luke, B.T.; Kroth, H.; Sayer, J.M.; Jerina, D.M.; Pommier, Y. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry, 2002, 41(5), 1428-1435. (Pubitemid 34112730)
89. Iwasa, K.; Moriyasu, M.; Yamori, T.; Turuo, T.; Lee, D.U.; Wiegrebe, W. In vitro cytotoxicity of the protoberberine-type alkaloids. J. Nat. Prod., 2001, 64(7), 896-898. (Pubitemid 32729899)
90. Palumbo, M.; Gatto, B.; Moro, S.; Sissi, C.; Zagotto, G. Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex. Biochim. Biophys. Acta, 2002, 1587(2-3), 145-154. (Pubitemid 34655784)
91. Sanders, M.M.; Liu, A.A.; Li, T.K.; Wu, H.Y.; Desai, S.D.; Mao, Y.; Rubin, E.H.; LaVoie, E.J. Makhey D, Liu LF. Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells. Biochem. Pharmacol., 1998, 56(9), 1157-1166. (Pubitemid 28511238)
92. Qin, Y.; Pang, J.Y.; Chen, W.H.; Zhao, Z.Z.; Liu, L.; Jiang, Z.H. Inhibition of DNA topoisomerase I by natural and synthetic mono- and dimeric protoberberine alkaloids. Chem. Biodivers., 2007, 4(3), 481-487.
93. Pang, J.Y.; Long, Y.H.; Chen, W.H.; Jiang, Z.H. Amplification of DNA-binding affinities of protoberberine alkaloids by appended polyamines. Bioorg. Med. Chem. Lett., 2007, 17(4), 1018-1021.
94. Prado, S.; Michel, S.; Tillequin, F.; Koch, M.; Pfeiffer, B.; Pierré, A.; Léonce, S.; Colson, P.; Baldeyrou, B.; Lansiaux, A.; Bailly, C. Synthesis and cytotoxic activity of benzo[c][1,7] and [1,8]phenanthrolines analogues of nitidine and fagaronine. Bioorg. Med. Chem., 2004, 12(14), 3943-3953. (Pubitemid 38798256)
95. Janin, Y.L.; Croisy, A.; Riou, J.F.; Bisagni E. Synthesis and evaluation of new 6-amino- substituted benzo[c]phenanthridine derivatives J. Med. Chem., 1993, 36(23), 3686-3692 (Pubitemid 24004367)
96. Li, D.; Zhao, B.; Sim, S.P.; Li, T.K.; Liu, A.; Liu, L.F., LaVoie, E.J. 8,9-Methylenedioxybenzo[i]phenanthridines: Topoisomerase I-Targeting activity and cytotoxicity. Bioorg. Med. Chem., 2003, 11(17), 3795-3805. (Pubitemid 36952278)
97. Ruchelman, A.L.; Singh, S.K.; Ray, A.; Wu, X.H.; Yang, J.M.; Li, T.K.; Liu, A.; Liu, L.F.; LaVoie, E.J. 5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg. Med. Chem., 2003, 11(9), 2061-2073. (Pubitemid 36379023)
98. Singh, S.K.; Ruchelman, A.L.; Li, T.K.; Liu, A.; Liu, L.F.; LaVoie, E.J. Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. J. Med. Chem., 2003, 46(11), 2254-2257. (Pubitemid 36583504)
99. Kiselev, E.; Dexheimer, T.S.; Pommier, Y.; Cushman, M. Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents. J. Med. Chem., 2010, 53(24), 8716-8726.
100. Kerrigan, J.E.; Pilch, D.S.; Ruchelman, A.L.; Zhou, N.; Liu, A.; Liu, L.; LaVoie, E.J. 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h] [1,6]naphthyridin-6-ones and related compounds as TOP1-targeting agents: influence of structure on the ternary cleavable complex formation. Bioorg. Med. Chem. Lett., 2003, 13(20), 3395-3399. (Pubitemid 37141395)
101. Ruchelman, A.L.; Kerrigan, J.E.; Li, T.K.; Zhou, N.; Liu, A.; Liu, L.F.; LaVoie, E.J. Nitro and amino substitution within the A-ring of 5H-8,9- dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: influence on topoisomerase I-targeting activity and cytotoxicity. Bioorg. Med. Chem., 2004, 12(13); 3731-3742. (Pubitemid 38746877)
102. Zhu, S.; Ruchelman, A.L.; Zhou, N.; Liu, A.; Liu, L.F.; LaVoie, E.J. 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg. Med. Chem., 2006, 14(9), 3131-3143.
103. Ruchelman, A.L.; Zhu, S.; Zhou, N.; Liu, A.; Liu, L.F.; LaVoie, E.J. Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity. Bioorg. Med. Chem. Lett., 2004, 14(22), 5585- 5589.
104. Zhu, S.; Ruchelman, A.L.; Zhou, N.; Liu, A.A.; Liu, L.F.; LaVoie, E.J. Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12- carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents. Bioorg. Med. Chem., 2005, 13(24), 6782-6794. (Pubitemid 41571224)
105. Reddy, M.V.; Rao, M.R.; Rhodes, D.; Hansen, M.S.; Rubins, K.; Bushman, F.D.; Venkateswarlu, Y.; Faulkner, D.J. Lamellarin alpha 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. J. Med. Chem., 1999, 42(11), 1901-1907. (Pubitemid 29269623)
106. Pla, D.; Albericio, F.; Alvarez, M. Recent advances in lamellarin alkaloids: isolation, synthesis and activity. Anticancer Agents Med. Chem., 2008, 8(7), 746-760.
107. Bailly, C. Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids. Curr. Med. Chem. Anticancer Agents, 2004, 4(4), 363-378. (Pubitemid 38923329)
108. Reddy, S. M.; Srinivasulu, M.; Satyanarayana, N.; Kondapi, A. K.; Venkateswarlu, Y. New potent cytotoxic lamellarin alkaloids from Indian ascidian Didemnum obscurum. Tetrahedron, 2005, 61(39), 9242-9247. (Pubitemid 41206483)
109. Marco, E.; Laine, W.; Tardy, C.; Lansiaux, A.; Iwao, M.; Ishibashi, F.; Bailly, C.; Gago, F. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J. Med. Chem., 2005, 48(11), 3796-3807. (Pubitemid 40776854)
110. Facompré, M.; Tardy C.; Bal-Mayeu C.; Colson P.; Perez C.;Manzanares I.; Cuevas C.; Bailly, C. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res., 2003, 63(21), 7392-7399. (Pubitemid 37413481)
111. Ishibashi, F.; Tanabe, S.; Oda, T.; Iwao, M. Synthesis and structure-activity relationship study of lamellarin derivatives. J. Nat. Prod., 2002, 65(4), 500-504. (Pubitemid 34456932)
112. Chittchang, M.; Batsomboon, P.; Ruchirawat, S.; Ploypradith, P. Cytotoxicities and structure-activity relationships of natural and unnatural lamellarins toward cancer cell lines. Chem. Med. Chem., 2009, 4(3), 457-465.
113. Pla, D.; Marchal, A.; Olsen, C. A.; Francesch, A.; Cuevas, C.; Albericio, F.; Álvarez, M. Synthesis and structure-activity relationship study of potent cytotoxic analogues of the marine alkaloid Lamellarin D. J. Med. Chem., 2006, 49(11), 3257-3268. (Pubitemid 43830523)
114. Boonya-udtayan, S.; Yotapan, N., Woo, C.; Bruns, C.J.; Ruchirawat, S.; Thasana, N. Synthesis and biological activities of azalamellarins. Chem. Asian J., 2010, 5(9), 2113-2123.
115. Ohta, T.; Fukuda, T.; Ishibashi, F.; Iwao, M. Design and synthesis of lamellarin D analogues targeting topoisomerase I. J. Org. Chem., 2009, 74(21), 8143-8153.
116. Pla, D.; Francesch, A.; Calvo, P.; Cuevas, C.; Aligue, R.; Albericio, F.; Alvarez, M., Lamellarin D bioconjugates I: Synthesis and cellular internalization of PEG-derivatives. Bioconjugate Chem., 2009, 20(6), 1100-1111.
117. Pla, D.; Marti, M.; Farrera-Sinfreu, J.; Pulido, D.; Francesch, A.; Calvo, P.; Cuevas, C.; Royo, M.; Aligue, R.; Albericio, F.; Alvarez, M. Lamellarin D bioconjugates II: Synthesis and cellular internalization of dendrimer and nuclear location signal derivatives. Bioconjugate Chem., 2009, 20(6), 1112-1121.
118. Cananzi, S.; Merlini, L.; Artali, R.; Beretta, G.L.; Zaffaroni, N.; Dallavalle, S. Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D. Bioorg. Med. Chem., 2011, 19(16), 4971-4984.
119. Ishiyama, D.; Kanai, Y.; Senda, H.; Iwatani, W.; Iwatani, W.; Konno, H.; Kanazawa, S. Novel human topoisomerase I inhibitors, topopyrones A, B, C and D. II. Structure elucidation. J. Antibiot. (Tokyo), 2000, 53(9), 873-878.
120. Kanai, Y.; Ishiyama, D.; Senda, H.; Iwatani, W.; Takahashi, H., Konno, H.; Tokumasu, S., Kanazawa, S. Novel human topoisomerase I inhibitors, topopyrones A, B, C and D. I. Producing strain, fermentation, isolation, physico-chemical properties and biological activity. J. Antibiot. (Tokyo), 2000, 53(9), 863-872.
121. Leteurtre, F.; Fujimori, A.; Tanizawa, A.; Chhabra, A.; Mazumder, A.; Kohlhagen, G.; Nakano, H.; Pommier, Y. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J Biol Chem., 1994, 269(46), 28702-28707. (Pubitemid 24366706)
122. Dallavalle, S.; Gattinoni, S.; Mazzini, S.; Scaglioni, L.; Merlini, L.; Tinelli, S.; Beretta, G.L.; Zunino, F. Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(4), 1484-1489. (Pubitemid 351226518)
123. Fujii, N.; Yamashita, Y.; Mizukami, T.; Nakano, H. Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity for saintopin-type antibiotics. Mol Pharmacol., 1997, 51(2), 269-276. (Pubitemid 27074148)
124. Scaglioni, L.; Mazzini, S.; Mondelli, R.; Dallavalle, S.; Gattinoni, S.; Tinelli, S.; Beretta, G.L.; Zunino, F.; Ragg, E. Interaction between double helix DNA fragments and a new topopyrone acting as human topoisomerase I poison. Bioorg. Med. Chem., 2009, 17(2), 484-491.
125. Xiao, X.; Cushman, M. An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes. J Am Chem Soc., 2005, 127(28), 9960-9961. (Pubitemid 40995415)
126. Valenti, M.; Nieves-Neira, W.; Kohlhagen, G.; Kohn, K.W.; Wall, M.E.; Wani, M.C.; Pommier, Y. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol. Pharmacol., 1997, 52(1), 82-87. (Pubitemid 27318622)
127. Xiao, X.; Antony, S.; Pommier, Y.; Cushman, M. On the binding of indeno[1,2-c]isoquinolines in the DNA-topoisomerase I cleavage complex. J Med Chem., 2005, 48(9), 3231-3238. (Pubitemid 40628043)
128. Marchand, C.; Antony, S.; Kohn, K.W.; Cushman, M.; Ioanoviciu, A.; Staker, B.L.; Burgin, A.; Stewart, L.; Pommier, Y. A Novel Norindenoisoquinoline Structure Reveals a Common Interfacial Inhibitor Paradigm for Ternary Trapping of the Topoisomerase I-DNA Complex. Mol. Cancer Ther., 2006, 5(2), 287-295.
129. Song, Y.L.; Cushman, M. The Binding Orientation of a Norindenoisoquinoline in the Topoisomerase I-DNA Cleavage Complex Is Primarily Governed by pi-pi Stacking Interactions. J. Phys. Chem. B., 2008, 112(31), 9484-9489.
130. Jaxel, C.; Capranico, G.; Kerrigan, D.; Kohn, K.W.; Pommier, Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem., 1991, 266(30), 20418-20423. (Pubitemid 21908475)
131. Antony, S.; Jayaraman, M.; Laco, G.; Kohlhagen, G.; Kohn, K.W., Cushman, M.; Pommier, Y. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecinresistant topoisomerases I. Cancer Res., 2003, 63(21), 7428-7435. (Pubitemid 37413485)
132. Shao, R.G.; Cao, C.X.; Shimizu, T.; O'Connor, P.M.; Kohn, K.W., Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 1997, 57(18), 4029- 4035.
133. Strumberg, D.; Pilon, A.A.; Smith, M.; Hickey, R.; Malkas, L.; Pommier, Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol., 2000, 20(11), 3977-3987. (Pubitemid 30314496)
134. Shao, R.G.; Cao, C.X.; Zhang, H.; Kohn, K.W.; Wold, M.S.; Pommier, Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J., 1999, 18(5), 1397-1406. (Pubitemid 29110323)
135. Lee, S.; Lee, H.S.; Baek, M.; Lee, D.Y.; Bang, Y.J.; Cho, H.N.; Lee, Y.S.; Ha, J.H.; Kim, H.Y.; Jeoung, D.I. MAPK signaling is involved in camptothecin-induced cell death. Mol. Cells, 2002, 14(3), 348-354.
136. Kinders, R.J.; Hollingshead, M.; Lawrence, S.; Ji, J.; Tabb, B.; Bonner, W.M.; Pommier, Y.; Rubinstein, L.; Evrard, Y.A.; Parchment, R.E.; Tomaszewski, J.; Doroshow, J.H. Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin. Cancer Res., 2010, 16(22), 5447-5457.
137. Huang, X.; Traganos, F.; Darzynkiewicz, Z. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle, 2003, 2(6), 614-619.
138. Furuta, T.; Takemura, H.; Liao, Z.Y.; Aune, G.J.; Redon, C.; Sedelnikova, O.A.; Pilch, D.R.; Rogakou, E.P.; Celeste, A.; Chen, H.T.; Nussenzweig, A.; Aladjem, M.I.; Bonner, W.M.; Pommier, Y. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem., 2003, 278(22), 20303-20312. (Pubitemid 36799229)
139. Han, B.; Stockwin, L.H.; Hancock, C.; Yu, S.X.; Hollingshead, M.G.; Newton, D.L. Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor. J. Proteome Res., 2010, 9(8), 4016-4027.
140. Antony, S.; Kohlhagen, G.; Agama, K.; Jayaraman, M.; Cao, S.; Durrani, F.A.; Rustum, Y.M.; Cushman, M., Pommier, Y. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol. Pharmacol., 2005, 67(2), 523-530. (Pubitemid 40216745)
141. Antony, S.; Agama, K.K.; Miao, Z.H.; Takagi, K.; Wright, M.H.; Robles, A.I.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res., 2007, 67(21), 10397-10405. (Pubitemid 350070815)
142. Facompre, M.; Goossens, J.F.; Bailly, C. Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1. Biochem. Pharmacol., 2001, 61(3), 299-310. (Pubitemid 32126668)
143. Saif, M.W.; Diasio, R.B. Edotecarin: a novel topoisomerase I inhibitor. Clin. Colorectal Cancer, 2005, 5(1), 27-36.
144. Li, T.K.; Houghton, P.J.; Desai, S.D.; Daroui, P.; Liu, A.A.; Hars, E.S.; Ruchelman, A.L.; LaVoie, E.J.; Liu, L.F. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res., 2003, 63(23), 8400-8407. (Pubitemid 37549495)
145. Sooryakumar, D.; Dexheimer, T.; Teicher, B.A.; Pommier, Y. Molecular and cellular pharmacology of the novel non-camptothecin topoisomerase I inhibitor, Genz-644282. Mol. Cancer Ther., 2011, 10(8), 1490-1499.
146. Houghton, P.J.; Lock, R.; Carol, H.; Morton, C.L.; Gorlick, R.; Anders Kolb, E., Keir, S.T.; Reynolds, C.P.; Kang, M.H.; Maris, J.M.; Billups, C.A.; Zhang, M.X.; Madden, S.L.; Teicher, B.A.; Smith, M.A. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2011, http://onlinelibrary.wiley.com/doi/10. 1002/pbc.23016/pdf (Accessed Sepetember 22, 2011)
147. Kurtzberg, L.S.; Roth, S.; Krumbholz, R.; Crawford, J.; Bormann, C.; Dunham, S.; Yao, M.; Rouleau, C.; Bagley, R.G.; Yu, X.J.; Wang, F.; Schmid, S.M.; Lavoie, E.J.; Teicher, B.A. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin. Cancer Res., 2011, 17(9), 2777-2787.
148. Ruchelman, A.L.; Houghton, P.J.; Zhou, N.; Liu, A.; Liu, L.F.; LaVoie, E.J. 5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. J. Med. Chem., 2005, 48(3), 792-804. (Pubitemid 40209101)
149. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R.H.; Melillo, G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res., 2004, 64(4), 1475-1482. (Pubitemid 38235619)
150. Bertozzi, D.; Iurlaro, R.; Sordet, O.; Marinello, J.; Zaffaroni, N.; Capranico, G. Characterization of novel antisense HIF-1α transcripts in human cancers. Cell Cycle, 2011, 10(18), 3189-197.
151. Meng, F.; Nguyen, X.T.; Cai, X.; Duan, J.; Matteucci, M.; Hart, C.P. ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1 alpha accumulation. Anticancer Drugs, 2007, 18(4), 435-445. (Pubitemid 46712407)
152. Ballot, C.; Kluza, J.; Martoriati, A.; Nyman, U.; Formstecher, P.; Joseph, B.; Bailly, C.; Marchetti, P. Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D. Mol. Cancer Ther., 2009, 8(12), 3307-3317.
153. Ballot, C.; Kluza, J.; Lancel, S.; Martoriati, A.; Hassoun, S.; Mortier, L.; Vienne, J.C.; Briand, G.; Formstecher, P.; Bailly, C.; Neviere, R.; Marchetti, P. Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis, 2010, 15(7), 769-781.
154. Bayet-Robert, M.; Lim, S.; Barthomeuf, C.; Morvan, D. Biochemical disorders induced by cytotoxic marine natural products in breast cancer cells as revealed by proton NMR spectroscopy-based metabolomics. Biochem. Pharmacol., 2010, 80(8), 1170-1179.
155. Baunbæk, D.; Trinkler, N.; Ferandin, Y.; Lozach, O.; Ploypradith, P.; Ruchirawat, S.; Ishibashi, F., Iwao, M. Meijer, L. Anticancer alkaloid lamellarins inhibit protein kinases. Mar. Drugs, 2008, 6(4), 514-527. (Pubitemid 352774411)
156. Beretta GL, Perego P, Zunino F. Mechanisms of cellular resistance to camptothecins. Curr. Med. Chem., 2006, 13(27), 3291-305. (Pubitemid 44669776)
157. Labourier, E.; Riou, J.F.; Prudhomme, M.; Carrasco, C.; Bailly, C.; Tazi, J. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res., 1999, 59(1), 52-55. (Pubitemid 29062954)
158. Urasaki, Y.; Laco, G.; Takebayashi, Y.; Bailly, C.; Kohlhagen, G.; Pommier, Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res., 2001, 61(2), 504-508. (Pubitemid 32128607)
159. Woo, M.H.; Vance, J.R.; Marcos, A.R.; Bailly, C.; Bjornsti, M.A. Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin. J. Biol. Chem. 2002, 277(6), 3813-3822.
160. Saif, M.W.; Sellers, S.; Diasio, R.B.; Douillard, J.Y. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5- fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anticancer Drugs, 2010, 21(7), 716-723.
161. Miao, Z.H.; Player, A.; Shankavaram, U.; Wang, Y.H.; Zimonjic, D.B.; Lorenzi, P.L.; Liao, Z.Y.; Liu, H.; Shimura, T.; Zhang, H.L.; Meng, L.H.; Zhang, Y.W.; Kawasaki, E.S.; Popescu, N.C.; Aladjem, M.I.; Goldstein, D.J.; Weinstein, J.N.; Pommier Y. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res., 2007, 67(18), 8752-8761. (Pubitemid 47437451)
162. Feng, W.; Satyanarayana, M.; Tsai, Y.C.; Liu, A.A.; Liu, L.F.; LaVoie, E.J.Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9- methylenedioxy-5-[(2-N,N,Ntrimethylammonium) ethyl]dibenzo[c,h][1,6] naphthyridin-6-one iodide. Eur. J. Med. Chem., 2009, 44(9), 3433-3438.
163. Holden, J.A.; Wall, M.E.; Wani, M.C.; Manikumar, G. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Arch. Biochem. Biophys., 1999, 370(1), 66-76. (Pubitemid 29476951)
164. Iwasaki, H.; Okabe, T.; Takara, K.; Toda, T.; Shimatani, M.; Oku, H. Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam. Cancer Chemother. Pharmacol., 2010, 65(4), 719-726.
165. Iwasaki, H.; Okabe, T.; Takara, K.; Yoshida, Y.; Hanashiro, K.; Oku, H. Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of nitidine. Cancer Chemother. Pharmacol., 2010, 66(5), 953-959.
166. Theile, D.; Grebhardt, S.; Haefeli, W.E.; Weiss, J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem. Pharmacol., 2009, 78(11), 1366-1373.
167. Peigñan, L.; Garrido, W.; Segura, R.; Melo, R.; Rojas, D.; Cárcamo, J.G.; San Martín, R.; Quezada, C. Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro. Neurochem. Res., 2011, 36(8), 1397-1406.
168. Gatti, L.; Cossa, G.; Beretta, G.L.; Zaffaroni, N.; Perego, P. Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy. Curr. Med. Chem., 2011, 18(27), 4237-4249.
169. Zhang, H.; Barceló, J.M.; Lee, B.; Kohlhagen, G.; Zimonjic, D.B.; Popescu, N.C.; Pommier, Y. Human mitochondrial topoisomerase I. Proc Natl Acad Sci U S A., 2001, 98(19), 10608-10613. (Pubitemid 32878668)
170. de la Loza, M.C.; Wellinger, R.E. A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan. Nucleic Acids Res., 2009, 37(4) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651790/pdf/gkn1087.pdf (Accessed December 2, 2011).
171. Diana, P.; Martorana, A.; Barraja, P.; Montalbano, A.; Dattolo, G.; Cirrincione, G.; Dall'acqua, F.; Salvador, A.; Vedaldi, D.; Basso, G.; Viola, G. Isoindolo[2,1-a]quinoxaline derivatives, novel potent antitumor agents with dual inhibition of tubulin polymerization and topoisomerase I. J. Med. Chem., 2008, 51(8), 2387-2399. (Pubitemid 351628500)
172. Perego, P.; Cossa, G.; Tinelli, S.; Corna, E.; Carenini, N.; Gatti, L.; De Cesare, M.; Ciusani, E.; Zunino, F.; Luison, E.; Canevari, S.; Zaffaroni, N.; Beretta, G.L. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition. Biochem. Pharmacol., 2012, 83(1), 27-36.
173. Beretta, G.L.; Cossa, G.; Gatti, L.; Zunino, F.; Perego, P. Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment. Curr. Med. Chem., 2010, 17(15), 1500-1508.
174. Huang, S.Y.; Pommier, Y.; Marchand, C. Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin. Ther. Pat., 2011, 21(9), 1285-1292.
175. Fukuda, M.; Nishio, K.; Kanzawa, F.; Ogasawara, H.; Ishida, T.; Arioka, H.; Bojanowski, K. Oka, M.; Saijo, N. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res., 1996, 56(4), 789-793.
176. El-Khamisy, S.F.; Saifi, G.M.; Weinfeld, M.; Johansson, F.; Helleday, T.; Lupski, J.R.; Caldecott, K.W. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature, 2005, 434(7029), 108-113. (Pubitemid 40349394)
177. Plo, I.; Liao, Z.Y.; Barceló, J.M.; Kohlhagen, G.; Caldecott, K.W.; Weinfeld, M.; Pommier, Y. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst)., 2003, 2(10), 1087-1100. (Pubitemid 39662824)
178. Svendsen, J.M.; Smogorzewska, A.; Sowa, M.E.; O'Connell, B.C.; Gygi, S.P.; Elledge, S.J.; Harper, J.W. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell., 2009, 138(1), 63-77.
179. Saulnier, M.G.; Balasubramanian, B.N.; Long, B.H.; Frennesson, D.B.; Ruediger, E.; Zimmermann, K.; Eummer, J.T.; St Laurent, D.R.; Stoffan, K.M.; Naidu, B.N.; Mahler, M.; Beaulieu, F.; Bachand, C.; Lee, F.Y.; Fairchild, C.R.; Stadnick, L.K.; Rose, W.C.; Solomon, C.; Wong, H.; Martel, A.; Wright, J.J.; Kramer, R.; Langley, D.R.; Vyas, D.M. Discovery of a fluoroindolo[2,3-a] carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11. J Med Chem., 2005, 48(7), 2258-2261. (Pubitemid 40520515)
180. Yoshinari, T.; Yamada, A.; Uemura, D.; Nomura, K.; Arakawa, H.; Kojiri, K.; Yoshida, E.; Suda, H.; Okura, A. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res., 1993, 53(3), 490-494. (Pubitemid 23059425)